Merck & Co., Inc. (MRK) is a global research-driven biopharmaceutical company headquartered in Rahway, New Jersey. With a market capitalization of $366 billion, the company develops, manufactures, and markets prescription medicines, vaccines, biologic therapies, and animal health products, with a focus on oncology, infectious diseases, immunology, and other major therapeutic areas.
Shares of this biopharmaceutical giant have significantly outperformed the broader market over the past year. MRK has climbed 75.4% during this period, compared with a nearly 10.5% gain in the broader S&P 500 Index ($SPX). MRK is also up 37.4% year-to-date, outperforming the index's 10.6% gain over the same period.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
Narrowing the comparison, MRK has also outperformed the iShares U.S. Pharmaceuticals ETF (IHE), which has gained 39.8% over the past year. The stock has maintained its lead year-to-date, while IHE has advanced 25.8%.
www.barchart.com On Oct. 29, Merck & Co. reported its Q3 2026 earnings, with shares rising 3.8% on the same day as results exceeded analyst expectations on both revenue and earnings. Worldwide sales increased 4.6% year over year to $18.09 billion, driven by continued strength in oncology and animal health, along with contributions from newer products. However, non-GAAP EPS declined 3.5% to $2.49 from $2.58 in the year-ago quarter, partly reflecting higher operating expenses and net interest expense.
Alongside its results, Merck raised its full-year 2026 worldwide sales guidance to $66.8 billion to $67.3 billion, compared with its previous outlook of $66.3 billion to $67.3 billion. The company also increased its non-GAAP EPS guidance to $2.77 to $2.82 from $2.66 to $2.76, while narrowing its non-GAAP operating expense outlook to $42.4 billion to $42.9 billion from $42 billion to $42.7 billion. The revised EPS outlook includes one-time charges of $3.62 per share related to the Cidara acquisition, $2.31 per share for Terns Pharmaceuticals, and $0.12 per share for the SciBrunch licensing agreement.
For the current fiscal year, ending in December 2026, analysts expect MRK’s diluted EPS to decrease sharply by 68% to $2.87. Notably, the company has exceeded Wall Street’s consensus EPS estimates in each of the past four quarters.
Among the 28 analysts covering MRK stock, the consensus rating is “Moderate Buy.” That’s based on 16 “Strong Buy” ratings, two “Moderate Buy” ratings, nine “Hold” ratings, and one “Strong Sell” rating.
www.barchart.com The analyst configuration is more bearish than it was a month ago, when MRK had 17 “Strong Buy” recommendations.
On Nov. 2, 2026, Leerink Partners analyst Daina Graybosch maintained a “Buy” rating on Merck & Co. and raised her price target to $162 from $161.
The mean analyst price target of $161.67 represents an 11.8% premium to MRK’s current share price, while the Street-high target of $180 suggests a potential premium of 24.4%.
On the date of publication, Abhishek Bhuyan did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Visa Just Hiked Its Dividend by More Than 16%, But Investors Should Consider Waiting for V to Pull Back Before Buying. AMD Stock Pops on $17B Q4 Revenue Guide. Traders Shouldn't Overlook a $3B Inventory Gamble and Collapsing Free Cash Flow. Dear Uber Stock Fans, Mark Your Calendars for November 4 Ahead of Qualcomm Earnings, Here's What Barchart Data Says Comes Next for QCOM Stock